Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.

نویسندگان

  • Jinali R Patel
  • Sinthu S Ranjan
  • Barry N Wasserman
چکیده

PURPOSE OF REVIEW To review the most recent literature regarding the clinical experience of antivascular endothelial growth factor (anti-VEGF) therapies in the treatment of retinopathy of prematurity (ROP). RECENT FINDINGS Anti-VEGF agents in stage 3+ and aggressive posterior ROP have been shown to induce rapid ROP regression. However, significant reoccurrence rates can require repeat injections and thus longer term and more frequent follow-up. Initial studies reflect conflicting evidence regarding significant systemic side effects of these treatments, and outcomes in these patients past the first few years of life are yet to be definitively determined. SUMMARY Although anti-VEGF therapies show promise in the treatment of ROP, frequent reoccurrences and lack of thorough data about long-term side effects of pharmacologic intervention necessitate further research before anti-VEGF agents become the mainstay of ROP management.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Retinopathy of prematurity: An update on screening and management.

Retinopathy of prematurity is a proliferative disorder of the developing retinal blood vessels in preterm infants. The present practice point reviews new information regarding screening and management for retinopathy of prematurity, including the role of risk factors in screening, optimal scheduling for screening examinations, pain management, digital retinal photography and antivascular endoth...

متن کامل

The efficacy of intravitreal antivascular endothelial growth factor as primary treatment of retinopathy of prematurity: Experience from a tertiary hospital.

BACKGROUND Retinopathy of prematurity (ROP) is a vasoproliferative disease affecting premature babies and a major cause of blindness in childhood. Appropriate screening and treatment can prevent blindness. OBJECTIVE To report on the efficacy of using antivascular endothelial growth factor (bevacizumab) as first-line therapy in ROP. METHODS This was a retrospective analysis of patients with ...

متن کامل

Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.

A growing body of evidence indicates that antivascular endothelial growth factor (VEGF) therapy is effective in the treatment of retinopathy of prematurity (ROP). We conducted a comprehensive literature review on refractive outcomes of anti-VEGF treatments compared to laser treatment or a combination of laser therapy and anti-VEGF injections. Of the 9 studies analyzed, the final mean refractive...

متن کامل

Retinopathy of Prematurity: Pathogenesis and Current Treatment Options.

Retinopathy of prematurity (ROP) is a vasoproliferative retinal disorder that continues to be the major cause of preventable childhood blindness worldwide. Its incidence is inversely proportional to gestational age and birth weight. Approximately 65 percent of neonates with <1,250 g birth weight and 80 percent of those with 1,000 g birth weight will develop some degree of ROP. ROP can cause mil...

متن کامل

Emerging roles for antiangiogenesis factors in management of ocular disease

The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatmen...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Current opinion in ophthalmology

دوره 27 5  شماره 

صفحات  -

تاریخ انتشار 2016